Loading
The methylation blood test now sold as Galleri detected half of all cancers and one in six stage I cancers in 4,077 people, while wrongly flagging one healthy person in 200, and named the organ correctly in 89% of positives.
The third and final substudy of the Circulating Cell-free Genome Atlas validated a multi-cancer early detection test using cell-free DNA methylation sequencing with machine learning in 4,077 participants (2,823 cancer, 1,254 non-cancer confirmed at one year). Specificity for cancer signal detection was 99.5%; overall sensitivity was 51.5%, rising by stage (I 16.8%, II 40.4%, III 77.0%, IV 90.1%). Stage I to III sensitivity was 67.6% in 12 pre-specified cancers accounting for about two-thirds of US cancer deaths and 40.7% across all cancers. Cancer signals were detected across more than 50 cancer types and accuracy of cancer signal origin prediction was 88.7%.
Methylation-based screening is real but weakest exactly where pancreatic cancer needs it, at stage I, which is why high-risk surveillance rather than population screening carries the field here.
Shares CCGA (Circulating Cell-free Genome Atlas), Cell-free DNA methylation tests, GRAIL, Cell-free DNA (cfDNA).
Shares CCGA (Circulating Cell-free Genome Atlas), Cell-free DNA methylation tests, GRAIL, Galleri.
Shares GRAIL, Galleri, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares GRAIL, Galleri, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares GRAIL, Galleri, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares GRAIL, Galleri, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares GRAIL, Galleri, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares GRAIL, Galleri, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/